Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Chugai Sees Avastin Sales Of Y7 Billion By End-March 2008 (Japan)

This article was originally published in PharmAsia News

Executive Summary

Chugai Pharmaceutical Co. expects cancer drug Avastin to generate sales of around Y7 billion in the nine months from July to the end of March 2008. Swiss drugmaker Roche Holding AG owns a majority stake in Chugai. The Japanese government has set the price for Avastin at Y50,291 for a 100 milligram dose. The price was lower than what analysts had expected for the drug, which hinders the growth of tumors by starving them of blood supply. Avastin was approved by the Japanese Ministry of Health, Labor and Welfare last month for the treatment of advanced or refractory colorectal cancer. Despite the lower-than-expected price, analysts are still predicting that Avastin will become a blockbuster drug in Japan, saying it will gain approval for use in other cancers. (Click here for more - May Require Paid Subscription

You may also be interested in...



WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.

Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses

Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel